Beta-adrenergic blocking drugs in breast cancer: a perspective review
- 1 March 2012
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 4 (3), 113-125
- https://doi.org/10.1177/1758834012439738
Abstract
The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.Keywords
This publication has 57 references indexed in Scilit:
- Does β‐adrenoceptor blocker therapy improve cancer survival? Findings from a population‐based retrospective cohort studyBritish Journal of Clinical Pharmacology, 2011
- Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohortBreast Cancer Research and Treatment, 2011
- β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell linesBreast Cancer Research and Treatment, 2011
- The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast CancerCancer Research, 2010
- Synergism between immunostimulation and prevention of surgery-induced immune suppression: An approach to reduce post-operative tumor progressionBrain, Behavior, and Immunity, 2010
- Surgical Stress Promotes Tumor Growth in Ovarian CarcinomaClinical Cancer Research, 2009
- Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: Implications for stress-related enhancement of tumor progressionBrain, Behavior, and Immunity, 2009
- Neuroendocrine modulation of cancer progressionBrain, Behavior, and Immunity, 2009
- VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrineBrain, Behavior, and Immunity, 2008
- The influence of bio-behavioural factors on tumour biology: pathways and mechanismsNature Reviews Cancer, 2006